Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Read original at benzingaStocks · News reference
8-K filing — Inhibikase Therapeutics, Inc. (IKT)
Filed: 2026-08-26 AccNo: 0001193125-26-368296 Size: 150 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 26, 2026, 8:05 PM
- Checked
- Aug 26, 2026, 8:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
Read original at benzingaDanaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
Read original at benzinga